What question did this study set out to answer?

To evaluate the efficacy and safety of stapokibart in elderly patients with moderate-to-severe atopic dermatitis.

November 21, 2025International Journal of DermatologyOpen Access

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

View Full Paper

Ask AI

Bookmark

To evaluate the efficacy and safety of stapokibart in elderly patients with moderate-to-severe atopic dermatitis.
Eligible adults were randomized to receive stapokibart or placebo for 16 weeks followed by stapokibart for 36 weeks.
Elderly patients were classified as those aged 60 and above, while non-elderly patients were those aged 18 to less than 60.
Main efficacy outcomes included EASI‐75, IGA 0/1, and PP‐NRS reduction.
Elderly patients showed a 56.0% response for EASI‐75 with stapokibart versus 14.0% for placebo (p < 0.0001).
For IGA 0/1, response was 40.0% for stapokibart compared to 7.0% for placebo (p = 0.0003).
32.0% of elderly patients had a ≥ 4‐point reduction in PP‐NRS with stapokibart versus 7.0% for placebo (p = 0.0023).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial shows improved efficacy and safety of stapokibart in elderly patients with atopic dermatitis, indicating promising treatment options.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/6924e3ffc0ce034ddc34f594 https://doi.org/10.1111/ijd.70175

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows improved efficacy and safety of stapokibart in elderly patients with atopic dermatitis, indicating promising treatment options.

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

Key Points

Discussion

Implication

Cite This Study

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider